Unique ID issued by UMIN | UMIN000028719 |
---|---|
Receipt number | R000029246 |
Scientific Title | The study of the effect of cytapheresis against secondary failure of biologics therapy in inflammatory bowel disease maintenance therapy. |
Date of disclosure of the study information | 2017/09/01 |
Last modified on | 2018/08/20 06:53:24 |
The study of the effect of cytapheresis against secondary failure of biologics therapy in inflammatory bowel disease maintenance therapy.
CAPBIO
The study of the effect of cytapheresis against secondary failure of biologics therapy in inflammatory bowel disease maintenance therapy.
CAPBIO
Japan |
Ulcerative colitis
Crohn's disease
Medicine in general | Gastroenterology |
Others
NO
The choice of the therapy has CAP therapy, and it has been already known that it is effective for treatment to use this together, but the synergistic detailed mechanism is not apparent.
The CAP therapy is able to remove granular leukocyte an Ada column, cell sorva together, but cell sorva is able to remove lymphocytes.
B cells and the plasma cells are included in lymphocytes other than T cells and are aimed for the collection of of the data base about the effect that the removal of antibody forming cells gives in an antibiological preparation antibody level.
PK,PD
We judge combination therapy to have an effect with CRP, blood sedimentation, the improvement of the hemoglobin level by a blood test.
Also, in a practice range, we conduct a colonoscope or small intestine endoscopy and determine the difference of the effect with the control group by improvement of the endoscopic score (Rutgeerts score, Mayo score).
Observational
15 | years-old | <= |
65 | years-old | > |
Male and Female
The patients who would combine CAP therapy among the patients in maintenance administration with antiTNF - alpha antibody preparation (infliximab (Remicade), adalimumab (Humira)) among ulcerative colitis, patients with Crohn's disease with whole outpatient department and hospitalizing.
The patients who had the infection that the report based on the infection method needs.
20
1st name | |
Middle name | |
Last name | Hirotsugu Imaeda |
Shiga University of Medical Science
Division of Gastroenterology, Department of Medicine
Setatsukinowa-cho, Otsu
0775482217
imaeda@belle.shiga-med.ac.jp
1st name | |
Middle name | |
Last name | Hirotsugu Imaeda |
Shiga University of Medical Science
Division of Gastroenterology, Department of Medicine
Setatsukinowa-cho, Otsu
0775482217
imaeda@belle.shiga-med.ac.jp
Shiga University of Medical Science
Ministry of Health, Labour and Welfare
Japanese Governmental office
NO
2017 | Year | 09 | Month | 01 | Day |
Unpublished
Open public recruiting
2015 | Year | 05 | Month | 12 | Day |
2015 | Year | 06 | Month | 01 | Day |
2020 | Year | 03 | Month | 31 | Day |
2020 | Year | 06 | Month | 30 | Day |
2020 | Year | 09 | Month | 30 | Day |
2021 | Year | 03 | Month | 31 | Day |
None
2017 | Year | 08 | Month | 18 | Day |
2018 | Year | 08 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029246
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |